Boc-S-benzyl-L-cysteinol
Need Assistance?
  • US & Canada:
    +
  • UK: +

Boc-S-benzyl-L-cysteinol

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Boc-S-benzyl-L-cysteinol (CAS# 139428-96-9) is a useful research chemical.

Category
Amino Alcohol
Catalog number
BAT-000365
CAS number
139428-96-9
Molecular Formula
C15H23NO3S
Molecular Weight
297.40
Boc-S-benzyl-L-cysteinol
IUPAC Name
tert-butyl N-[(2R)-1-benzylsulfanyl-3-hydroxypropan-2-yl]carbamate
Synonyms
Boc-L-Cysteinol(Bzl); Boc-L-Cys(Bzl)-ol; (R)-tert-Butyl (1-(benzylthio)-3-hydroxypropan-2-yl)carbamate; tert-butyl N-[(2R)-1-benzylsulfanyl-3-hydroxypropan-2-yl]carbamate
Purity
≥ 98 % (HPLC)
Density
1.135 g/cm3
Melting Point
66-70 °C
Boiling Point
442.914 °C at 760 mmHg
Storage
Store at 2-8 °C
InChI
InChI=1S/C15H23NO3S/c1-15(2,3)19-14(18)16-13(9-17)11-20-10-12-7-5-4-6-8-12/h4-8,13,17H,9-11H2,1-3H3,(H,16,18)/t13-/m1/s1
InChI Key
MEZQRZMTIJTPIY-CYBMUJFWSA-N
Canonical SMILES
CC(C)(C)OC(=O)NC(CO)CSCC1=CC=CC=C1

Boc-S-benzyl-L-cysteinol, a versatile chemical compound commonly employed in biosciences, finds its application in a multitude of sophisticated ways. Here are four key applications:

Peptide Synthesis: Serving as a fundamental building block in peptide synthesis, Boc-S-benzyl-L-cysteinol plays a pivotal role in incorporating cysteine residues into peptides with precision. Its protective Boc and benzyl groups enable the seamless integration of cysteine without triggering undesired side reactions. This methodical approach allows for the efficient and accurate preparation of peptides, essential for advancing biochemical and therapeutic research.

Protein Engineering: In the realm of protein engineering, Boc-S-benzyl-L-cysteinol emerges as a crucial tool for introducing cysteine residues into proteins at designated locations. This controlled insertion is paramount for investigating protein functionalities, interactions, and stability. Furthermore, it facilitates the development of novel proteins endowed with enhanced properties, catering to diverse industrial and pharmaceutical applications with ingenuity.

Drug Development: Positioned at the forefront of drug development, Boc-S-benzyl-L-cysteinol serves as a key precursor for crafting cysteine-based drug candidates. Its selective reactivity empowers the generation of derivatives carrying potential therapeutic attributes. These derivatives undergo rigorous testing for efficacy against a spectrum of diseases, contributing significantly to the exploration of novel medications with promising treatment outcomes.

Bioconjugation: Within the domain of bioconjugation techniques, Boc-S-benzyl-L-cysteinol emerges as a critical component for linking biomolecules like proteins, peptides, or small molecules to a target molecule. By introducing cysteine residues with precision, it enables site-specific conjugation, a pivotal step in creating functionalized biomolecules. These bioconjugates find utility in targeted drug delivery systems, diagnostic tools, and therapeutic interventions, showcasing the versatility and significance of this compound in biomedical applications.

1. Half-sandwich complexes of iridium and ruthenium containing cysteine-derived ligands
María Carmona, Ricardo Rodríguez, Fernando J Lahoz, Pilar García-Orduña, Carlos Cativiela, José A López, Daniel Carmona Dalton Trans. 2017 Jan 17;46(3):962-976. doi: 10.1039/c6dt04341k.
The dimers [{(ηn-ring)MCl}2(μ-Cl)2] ((ηn-ring)M = (η5-C5Me5)Ir, (η6-p-MeC6H4iPr)Ru) react with the modified cysteines S-benzyl-l-cysteine (HL1) or S-benzyl-α-methyl-l-cysteine (HL2) affording cationic complexes of the formula [(ηn-ring)MCl(κ2N,S-HL)]Cl (1, 2) in good yield. Addition of NaHCO3 to complexes 1 and 2 gave equilibrium mixtures of neutral [(ηn-ring)MCl(κ2N,O-L)] (3, 4) and cationic [(ηn-ring)M(κ3N,O,S-L)]Cl (6Cl, 7Cl) complexes. Similar mixtures were obtained in one-pot reaction by successive addition of the modified cysteine and NaHCO3 to the above formulated dimers. Addition of the N-Boc substituted cysteine derivative S-benzyl-N-Boc-l-cysteine (HL3) and NaHCO3 to the dimers [{(ηn-ring)MCl}2(μ-Cl)2] affords the neutral compounds [(ηn-ring)MCl(κ2O,S-L3)] ((ηn-ring)M = (η5-C5Me5)Ir (5a), (η6-p-MeC6H4iPr)Ru (5b)). Complexes of the formula [(ηn-ring)MCl(κ3N,O,S-L)][SbF6] (6Sb-8Sb), in which the cysteine derivative acts as a tridentate chelate ligand, can be prepared by adding one equivalent of AgSbF6 to the solutions of compounds 5 or to the mixtures of complexes 3/6Cl and 4/7Cl. The amide proton of compounds 8aSb and 8bSb can be removed by addition of NaHCO3 affording the neutral complexes [(ηn-ring)M(κ3N,O,S-L3-H)] ((ηn-ring)M = (η5-C5Me5)Ir (9a), (η6-p-MeC6H4iPr)Ru (9b)). Complexes 9a and 9b can also be prepared by reacting the dimers [{(ηn-ring)MCl}2(μ-Cl)2] with HL3 and two equivalents of NaHCO3. The absolute configuration of the complexes has been established by spectroscopic and diffractometric means including the crystal structure determination of (RIr,RC,RS)-[(η5-C5Me5)Ir(κ3N,O,S-L1)][SbF6] (6aSb). The thermodynamic parameters associated with the epimerization at sulphur that the iridium compound [(η5-C5Me5)Ir(κ3N,O,S-L3-H)] (9a) undergoes have been determined through variable temperature 1H NMR studies.
2. Half-sandwich complexes of rhodium containing cysteine-derived ligands
María Carmona, Ricardo Rodríguez, Fernando J Lahoz, Pilar García-Orduña, Iñaki Osante, Carlos Cativiela, José A López, Daniel Carmona Dalton Trans. 2016 Sep 28;45(36):14203-15. doi: 10.1039/c6dt02411d. Epub 2016 Aug 17.
The modified cysteine ligand, S-benzyl-α-methyl-l-cysteine (HL2), was prepared from l-cysteine hydrochloride methyl ester. The reaction of commercial S-benzyl-l-cysteine (HL1) or HL2 with the dimer, [{(η(5)-C5Me5)RhCl}2(μ-Cl)2], gives rise to the cationic complexes, [(η(5)-C5Me5)RhCl(HL)]Cl (HL = HL1 (1), HL2 (2)), in which the cysteine ligand exhibits a κ(2)N,S coordination mode. In a basic medium, HL1 or HL2 reacts with [{(η(5)-C5Me5)RhCl}2(μ-Cl)2] to afford mixtures of two epimers at the metal centre of the neutral complexes, [(η(5)-C5Me5)RhCl(κ(2)N,O-L)] (HL = HL1 (3), HL2 (4)), in which amino carboxylate adopts a κ(2)N,O mode of coordination along with variable amounts of the cationic compounds, [(η(5)-C5Me5)Rh(κ(3)N,O,S-L)]Cl (HL = HL1 (6Cl), HL2 (7Cl)), which contain κ(3)N,O,S coordinated cysteine-derived ligands. However, in a basic medium, the N-Boc substituted cysteine S-benzyl-N-Boc-l-cysteine (HL3) only yields the κ(2)O,S coordinated derivative, [(η(5)-C5Me5)RhCl(κ(2)O,S-L3)] (5), as a mixture of two diastereomers depending on the configuration of the metal centre. The bidentate chelate complexes 3-5 react with AgSbF6 to give the hexafluoroantimonates [(η(5)-C5Me5)Rh(κ(3)N,O,S-L)][SbF6] (HL = HL1 (6Sb), HL2 (7Sb), HL3 (8Sb)) with tridentate coordination. Compound 8Sb reacts with NaHCO3 to give the neutral complex [(η(5)-C5Me5)Rh(κ(3)N,O,S-L3-H)] (9), which can also be prepared by reacting the dimer [{(η(5)-C5Me5)RhCl}2(μ-Cl)2] with HL3 in the presence of two equivalents of NaHCO3. The new compounds contain up to four stereogenic centres, namely, Rh, S, N, and C. The absolute configuration of the complexes has been established by spectroscopic and diffractometric investigations, including the crystal structure determination of [(η(5)-C5Me5)RhCl(κ(2)O,S-L3)] (5), [(η(5)-C5Me5)Rh(κ(3)N,O,S-L1)][SbF6] (6Sb), [(η(5)-C5Me5)Rh(κ(3)N,O,S-L2)][SbF6] (7Sb) and [(η(5)-C5Me5)Rh(κ(3)N,O,S-L3-H)] (9). Variable temperature (1)H NMR studies reveal the existence of epimerization processes and theoretical calculations were used to discriminate their nature.
3. Synthesis and characterization of novel organic/inorganic hybrid material with short peptide brushes generated on the surface
Florin Bucatariu, Ecaterina Stela Dragan, Frank Simon Biomacromolecules. 2007 Sep;8(9):2954-9. doi: 10.1021/bm700603q. Epub 2007 Aug 22.
A novel route to synthesize an organic/inorganic hybrid material containing short peptide chains attached on the surface (e.g., oligo(S-benzyl-L-cysteine)) was developed. Poly[N-(beta-aminoethylene)acrylamide] (PAEA) adsorbed onto silica particles surface (main diameter between 15 and 40 microm) was irreversibly fixed by the reaction between the accessible primary amino groups of the PAEA and 3,3',4,4'-benzophenone tetracarboxylic dianhydride (BTCDA). After the deposition of PAEA from a salt-free aqueous solution onto microporous silica particles and stabilization by a cross-linking reaction with BTCDA, five repeated coupling reactions of boc-S-benzyl-L-cysteine were performed. Changes in surface charges during the polyelectrolyte adsorption were studied by electrokinetic measurements. The cross-linking degree was a tool to control the surface charge of the PAEA/silica hybrid particles. X-ray photoelectron spectroscopy (XPS) was employed to obtain information about the amount of the adsorbed polyelectrolyte as well as the amount of the amino acid S-benzyl-L-cysteine that was covalently bound to the hybrid particle surface and polycondensed there. In the XPS spectra, the sulfur peaks (S 2p3/2, S 2p1/2, and S 2s) qualitatively and quantitatively indicated the presence of the amino acid on the hybrid material surface. After each step of coupling, the intensity of the S 2s peak was increased by a constant value. This indicates the oligopeptide growth. The novel hybrid material offers possibilities for subsequent derivatization reactions such as coupling other amino acids, peptides, obtaining hybrid ion exchange resins, and so forth.
Online Inquiry
Verification code
Inquiry Basket